BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy
Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based …
BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy Read More »